ICS are most beneficial for individuals with moderate to severe asthma or COPD, where inflammation is a primary feature. Epidemiological studies have shown that children, adults, and the elderly can all benefit from ICS, although the dosing and delivery method may vary across these groups. Special populations, such as those with a history of frequent exacerbations or hospitalizations, may derive significant benefit from consistent ICS use.
